Bispecific antibody constructs for cdh3 and cd3
Abstract
The present invention relates to a bispecific antibody construct comprising a first human binding domain that binds to human CDH3 on the surface of a target cell and a second binding domain that binds to human CDS on the surface of a cell. T. Furthermore, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide, and a host cell transformed or transitioned with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.</p> <p>(Automatic translation with Google Translate , without legal value)

Term
9.6 yearsto projected expiry
Projected expiry 18 April 2036, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
21 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21
44 members in 25 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 15164154 | European Patent Office (EPO) | A | |
| 15164154 | European Patent Office (EPO) | – | |
| 2016058482 | European Patent Office (EPO) | W |
Members44
| Document | Office | Kind | |
|---|---|---|---|
| CA2982682A1 | Canada | A1 | |
| WO2016166360A1 | World Intellectual Property Organization (WIPO) | A1 | |
| TW201704264A | Taiwan Province of China | A | |
| AR104309A1 | Argentina | A1 | |
| AU2016250023A1 | Australia | A1 | |
| SG11201708438WA | Singapore | A | |
| IL255076A0 | Israel | A0 | |
| IL255076D0 | Israel | D0 | |
| EP3283524A1 | European Patent Office (EPO) | A1 | |
| CN107750255A | China | A | |
| KR20180023892A | Republic of Korea | A | |
| CL2017002641A1 | Chile | A1 | |
| JP2018512860A | Japan | A | |
| US2018142021A1 | United States of America | A1 | |
| EA201792193A1 | Eurasian Patent Organization (EAPO) | A1 | |
| BR112017022326A2 | Brazil | A2 | |
| MX2017013348A | Mexico | A | |
| MA43197A | Morocco | A | |
| SG10201909308XA | Singapore | A | |
| US11028171B2 | United States of America | B2 | |
| JP6907124B2 | Japan | B2 | |
| AU2016250023B2 | Australia | B2 | |
| AU2022203450A1 | Australia | A1 | |
| TWI772258B | Taiwan Province of China | B | |
| CN107750255B | China | B | |
| US2023041876A1 | United States of America | A1 | |
| TW202311292A | Taiwan Province of China | A | |
| EP3283524B1 | European Patent Office (EPO) | B1 | |
| CN116063541A | China | A | |
| FI3283524T3 | Finland | T3 | |
| LT3283524T | Lithuania | T | |
| DK3283524T3 | Denmark | T3 | |
| IL255076B1 | Israel | B1 | |
| PT3283524T | Portugal | T | |
| PL3283524T3 | Poland | T3 | |
| ES2945313T3This record | Spain | T3 | |
| SI3283524T1 | Slovenia | T1 | |
| HUE061730T2 | Hungary | T2 | |
| IL255076B2 | Israel | B2 | |
| EP4276116A2 | European Patent Office (EPO) | A2 | |
| EP4276116A3 | European Patent Office (EPO) | A3 | |
| US11926666B2 | United States of America | B2 | |
| TWI858372B | Taiwan Province of China | B | |
| US2025092133A1 | United States of America | A1 |
Numbers
- Publication
- 2945313
- Application
- 16716617
Titles2
- Spanish
- Construcciones de anticuerpos biespecificos para CDH3 y CD3
- English
- Bispecific antibody constructs for CDH3 and CD3
Classification
- CPC, 15
- C07K16/28
- C07K16/2809
- C07K2317/622
- C07K2317/73
- C07K2317/92
- C07K2317/31
- C07K2317/33
- A61P35/00
- A61P35/02
- C07K2317/94
- C07K2317/565
- C07K2317/56
- A61K2039/505
- C07K2317/732
- C07K16/3053
- IPC, 2
- C07K16 28
- C07K16 46